Leadership Team
A highly experienced team with a strong track record of performance
The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics, a clinical-stage oncolytic immunotherapy company acquired in June 2018 by Merck and Co. Inc. for A$502 million.
Management Team
In the News
View our recent news stories
Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.
View All Stories
ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, San Diego
March 18, 2026
No Comments
Read More »
ImmVirX and BeOne Medicines Enter Clinical Collaboration to Evaluate IVX055 in Combination with tislelizumab
February 3, 2026
No Comments
Read More »